Clinical and pharmacogenetic features of patients with upper gastrointestinal lesions at a multidisciplinary hospital: the role of nonsteroidal anti-inflammatory drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications, but their use can be associated with a number of adverse reactions, including upper gastrointestinal lesions. The aim of the study was to identify clinical and pharmacogenetic factors associated with up...

Full description

Saved in:

Bibliographic Details
Published in:	Drug metabolism and personalized therapy Vol. 39; no. 2; p. 69
Main Authors:	Denisenko, Natalia P, Zhiryakova, Anna S, Sychev, Ivan V, Kryukov, Alexander V, Tuchkova, Svetlana N, Vakulenko, Olga Y, Averkov, Oleg V, Vechorko, Valery I, Mirzaev, Karin B, Sychev, Dmitry A
Format:	Journal Article
Language:	English
Published:	Germany 01-06-2024
Subjects:	Adult Aged Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Cyclooxygenase 1 Cytochrome P-450 CYP2C8 - genetics Cytochrome P-450 CYP2C9 - genetics Endoscopy, Digestive System Female Gastrointestinal Diseases - chemically induced Gastrointestinal Diseases - genetics Genotype Humans Male Middle Aged Pharmacogenetics Upper Gastrointestinal Tract - drug effects Upper Gastrointestinal Tract - pathology NSAIDs-induced gastropathy SNP COX-1 adverse reactions ulcers PTGS1
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications, but their use can be associated with a number of adverse reactions, including upper gastrointestinal lesions. The aim of the study was to identify clinical and pharmacogenetic factors associated with upper gastrointestinal lesions, including those linked to NSAIDs, in patients at a multidisciplinary hospital. The study included 92 patients (mean age 59.4±16.5 years; 47 women), who underwent esophagogastroduodenoscopy during inpatient treatment. Patients' intake of NSAIDs and gastroprotectors during the year before hospitalization was considered. Demographic, clinical, laboratory data of patients were compared between groups, including genotyping for , , , , , , and using real-time PCR. In NSAIDs patients, rs10306135 AT+TT genotypes increased the chance of developing gastrointestinal complications by 5.4 times (95 % CI=1.30-22.27). In total sample, smoking (OR=3.12, 95 % CI=1.15-8.46), and alcohol intake (OR=4.09, 95 % CI=1.05-15.87) increased odds of gastrointestinal damage. In NSAIDs patients omeprazole, famotidine and both famotidine and omeprazole during the last year were as ineffective as not taking gastroprotectors; in total sample famotidine (OR=0.19, 95 % CI=0.04-0.93) and two gastroprotectors (OR=0.13, 95 % CI=0.02-0.75) reduced the chance of upper gastrointestinal lesions. Pharmacogenetic features of patients may significantly contribute to the development NSAIDs-induced upper gastrointestinal injuries.
ISSN:	2363-8915